Talents Gathered Together to Strive to Write A New Chapter of Haematology—The 2023 Academic Meeting of the Vascular Biology Group of Experimental Hematology Committee of Chinese Association of Pathophysiology and the 2023 West China Hospital Academic Forum on Haematology Successfully Held

2023-03-29

Open the phone and scan

In order to promote the research of hematology in China, improve the clinical diagnosis and treatment of hematology, and exchange the progress of clinical and basic research and translational medicine research in the field of hematology, “The 2023 Academic Meeting of the Vascular Biology Group of Experimental Hematology Committee of Chinese Association of Pathophysiology and the 2023 West China Hospital Academic Forum on Haematology”, co-sponsored by the Vascular Biology Group of the Experimental Hematology Committee of the Chinese Society of Pathophysiology, Sichuan International Medical Exchange & Promotion Association (SCIMEA) and West China Hospital, Sichuan University,  was successfully held from March 17 to 19, 2023  in a combination of online and offline methods.


Scene of the meeting

On the morning of March 18, Prof. Niu Ting from West China Hospital of Sichuan University hosted the opening ceremony. Prof. Huang Xiaojun from Peking University People's Hospital/Beijing University Institute of Hematology, Prof. Wu Depei from the First Affiliated Hospital of Soochow University/Jiangsu Institute of Hematology, Prof. Hu Yu from Union Hospital/Institute of Hematology affiliated to Tongji Medical College of Huazhong University of Science and Technology, Prof. Liu Lunxu, Vice President of West China Hospital of Sichuan University  and Secretary General Zhang Mengfan from SCIMEA delivered speeches successively.


Prof. Niu Ting hosts the ceremony.

Prof. Huang Xiaojun expressed his warm welcome and heartfelt thanks to all the experts, scholars and peers attending the meeting. Prof. Huang said that experts and scholars in hematology have made great efforts for the cause of hematology in China. This meeting gathered many experts and provided a very good platform to test the achievements in the field of vascular biology in recent years, and he looked forward to the success of the meeting under the guidance of experts.


Prof. Huang Xiaojun delivers a speech.

Prof. Wu Depei expressed his warm congratulations on the convening of this meeting. Prof. Wu pointed out that from basic research to translational research in hematology, the Vascular Biology Group of the Experimental Hematology Committee of the Chinese Society of Pathophysiology has done a lot of work and achieved fruitful results. It is expected that this event will bring new inspiration to the participants, provide a strong impetus to clinical diagnosis and scientific research in hematology, and promote the prosperous development of hematology.


Prof. Wu Depei delivers a speech.

Prof. Hu Yu said that this meeting is inclusive and coherent, covering vaccine development, lymphoma, myeloma and leukemia, artificial intelligence, drug development and medical-industrial integration, etc.; in the meeting, the participants can share both the clinical experience analysis and the consensus analysis of guidelines, discuss the basic research progress and deliver the results transformation reports. He hoped that this meeting will advance the further development of hematology, promote standardized treatment in primary care, and benefit the hematology patients.


Prof. Hu Yu delivers a speech.

On behalf of West China Hospital of Sichuan University, Executive Vice President Liu Lunxu extended a warm welcome to all the experts present. He mentioned about, after 68 years’ development, the Department of Hematology in West China Hospital of Sichuan University, and under the leadership of successive leaders, has gradually developed into a national key clinical specialty of the Ministry of Health, a national training base for medical workers in hematology, a training base for hematology residents of the Ministry of Health and a quality control center for hematology in Sichuan Province. This meeting invited renowned experts in hematology and related fields from home and abroad to meet and discuss the cutting-edge issues related to hematology. It is believed that the meeting will bring new ideas and new thoughts to medical workers in the field of hematology and promote the cause of hematology to advance continuously.


Executive Vice President Liu Lunxu of West China Hospital, Sichuan University delivers a speech.

On behalf of SCIMEA, Secretary General Zhang Mengfan warmly congratulated on the convening of the meeting. She mentioned that as an international medical exchange promotion association, SCIMEA will give full play to the advantages of the industry platform, and focus on the five major sections of academic exchange, international standards, journal construction, industrial transformation and medical science popularization, providing more professional and precise services for hematologists with the spirit of no time to lose, exploring new development directions and making new contributions to the construction of a healthy Sichuan and healthy China.


Secretary General Zhang Mengfan of SCIMEA delivers a speech.


The academic session

After the opening ceremony, Academician Wei Yuquan from West China Hospital of Sichuan University/State Key Laboratory of Biotherapy at West China Hospital of Sichuan University and Prof. Zhao Weili from Ruijin Hospital affiliated to Shanghai Jiaotong University Medical College/Shanghai Institute of Hematology, gave keynote presentations.

Academician Wei Yuquan gave a lecture on cancer vaccine types and immune cell therapy for tumors. He mentioned that genomics brings new opportunities for tumor immunotherapy and gene therapy, and pointed out that synthetic biology is an emerging discipline of biology in the 21st century, which not only represents a new trend of biological system theory, but also a new focus of vaccine design. Academician Wei systematically summarized the scientific achievements made in the last 3 years since the outbreak of the COVID-19 pandemic, looked forward to the future developments, and elaborated on the COVID-19 virus research, clinical medicine and industrial aspects. In addition, Academician Wei talked about the significant differential advantage of BTK inhibitor JDB175 in brain penetration, and featuring high activity, good safety, and sufficient scientific basis for clinical development, it is expected to break through the dilemma of no drug available for patients with CNS lymphoma in the world.


“New Advances in Vaccine Research and Development”

Academician Wei Yuquan, the State Key Laboratory of Biotherapy at West China Hospital, Sichuan University

Prof. Zhao Weili explained how the microenvironment contributes to the cure of lymphoma from three major aspects: molecular biological characteristics of tumor and microenvironment (mediating immunotherapy resistance, cellular immunotherapy relapse, and key molecular markers), dynamic changes of lymphoma microenvironment (targeted intervention of immune checkpoint inhibitors and other drugs, and precise immune modulation targets), and molecular subtyping driven by lymphoma microenvironment (complementary molecular subtyping of tumor cell-derived lymphoma, and prospect of more precise targeted therapeutic strategies), bringing new concepts and new ideas to clinical medical personnel, and thus improving the clinical diagnosis and treatment of blood diseases in a comprehensive manner.


“Microenvironment of Lymphatic Tissues and Targeted Therapies”

Prof. Zhao Weili, Ruijin Hospital affiliated to Shanghai Jiaotong University Medical College/Shanghai Institute of Hematology

The meeting came to an end after a lively academic exchange and intriguing discussions. The meeting was full of excitement, featuring rich and diversified forms of communication, orderly connection from online to offline methods, and the interaction between basic and clinical aspects. It invited many experts from hematology departments at home and abroad to share their clinical experience and research results around new mechanisms, new bases and new advances in blood diseases, which will help to inspire new clinical thinking and continuous innovation and progress for workers in the field of hematology. It is believed that the success of this meeting will further improve the standardized diagnosis and treatment of hematology in Sichuan, promote the high-quality and innovative development of hematology in Sichuan, and continuously contribute to the construction of a healthy Sichuan!